The reaction of chloromethyl ethyl ether with bis(trimethylsilyl)uracil derivatives yield 1-(ethoxymethyl)pyrimidines 1a-d in good yield. lithiation of 1a-d with lithium diisopropylamide at -78°C, followed by reaction with diphenyl diselenide as an electrophile, gave 1-(ethoxymethyl)-6-(phenylselenenyl)uracils 2a-d in 70-80% yield. The 6-phenylselenenyl acyclic pyrimidines 2b and 2d eXhibited selective in vitro activity against HIV-1 and HIV-2 in primary human lymphocytes. The most potent compound was 1-(ethoxymethyl)-6-(phenylselenenyl)-5-ethyluracil 2d with a median effective concentration of 17nM in primary human lymphocytes and no discernable cytotoxicity in these cells or rapidly dividing CEM and Vero cells. Well characterized AZT-resistant virus was modestly (3 to 12-fold increase) cross-resistant to compounds 2b and 2d.
Introduction
Various 6-phenylthio substituted acyclic pyrimidines have been reported to inhibit the replication of human immunodeficiency virus type 1 (HIV-1) in various human T-cells (Miyasaka et al., 1989; Tanaka et aI., 1991a Tanaka et aI., , 1991b . Unlike normal nucleoside analogues these compounds are unique because they do not require phosphorylation in order to inhibit HIV-1 reverse transcriptase (Rl) (Saba et aI., 1991; Tanaka et aI., 1991c) and their spectrum of antiviral activity is limited to HIV-1 (Saba et aI., 1990) . Of significance was that 1-benzyloxy-5-ethyl-6-(phenylthio)uracil derivatives inhibited HIV-1 replication and HIV-1 RT, suggesting that the presence of an acyclic side chain with an intact free hydroxy function is not necessary for antiviral activity. More recently, we have reported the synthesis and antiviral activity of 6-phenylselenenyl acyclic pyrimidines against HIV-1. These compounds also inhibited human immunodeficiency virus type 2 (HIV-2), but did not inhibit viral RT (Goudgaon and Schinazi, 1991) . This class of acyclic pyrimidines containing 6-phenylselenenyl group is important to develop, not only because of their activity against various retroviruses, but also because their spectrum of activity is different from 1-[(2hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPl) and TISO-like compounds (Merluzzi et al., 1990; Pauwels et al., 1990; Goldman et aI., 1991; Saari et al., 1991; Tanaka et al., 1991a Tanaka et al., , 1991b . Substitution of a primary hydroxyl group for a hydrogen in the acyclic side chain may enhance the antiviral activity. To test such a hypothesis, we first synthesized 1-(ethoxymethyl)-6-(phenylseleneny-I)uracils 2a-d in a straightforward procedure ( Fig. 1) .
Results
1-(Ethoxymethyl)uracil 1a and its substituted analogues 1b-d were prepared via coupling bis(trimethylsilyl)uracil derivative with chloromethyl ethyl ether in the presence of 1.0 molar equivalent of stannic chloride in about 40-50% yield. Lithiation of 1a-d in THF with LDA (2.5 equivalents, for 1h) at -78°C generated, reqlospeclflcally, the C-6 lithiated species and subsequently reacted with diphenyl diselenide (2 equivalents, -70°C, for 1h). After allowing the reaction to warm up, the mixture was quenched with glacial AcOH. Chromatography on a silica gel column resulted in the isolation ofthe corresponding 6-phenylselenenyl analogues2a-d in excellent yield (70-80%) (Fig. 1) . The structure and purity of compounds 2a-d were confirmed by 1H NMR and microanalysis.
Antiviral activity and cytotoxicity of the compounds synthesized in this study are shown in Table 1 .
Discussion
Compounds 2b and 2d had excellent inhibitory effects against HIV-1 (strain LAV) in human peripheral blood mononuclear (PSM) cells. The medium effective concentrations (EC so ) for these compounds were 0.641LM and 0.017 fLM, respectively. Interestingly, replacement of the 5-alkyl group in uracil moiety by hydrogen or fluorine resulted in the decreased activity and increases their cytotoxicity. Whereas, the deoxy analogues of HEPT derivatives exhibited selective inhibition of HIV-1 (Baba et aI., 1991; Tanaka et al., 1991c) , this study demonstrated that the anti-HIV-1 and HIV-2 activity originally found in acyclic 6-phenylselenenyl pyrimidines (Goudgaon and Schinazi, 1991) was retained or improved in certain cases, by removing the hydroxyl group on the side chain. Compound 2d was found to have an EC so value of 0.006fLM in a plaque assay in HT4-6C cells infected with HIV-1 strain LAV (data not shown) confirming its potent activity against HIV-1 in vitro. The selenium containing compounds 2a and 2c exhibited cytotoxicity in Vero cells at concentrations close to their anti-HIV-1 activity, suggesting that toxicity in rapidly dividing cell such as bone marrow could pose a problem. All the compounds described in this paper were also evaluated in CEM cells, a T-Iymphoblastoid cell line. Compound 2c was the only one to demonstrate cytotoxicity in these cells having a median inhibitory concentration (IC so ) of 28.9 fLM. When tested in human PBM cells infected with HIV-2 (strain ROD-2), compounds 2a-d were found to have modest activity.
Their potency was similar to that observed against HIV-1, except for compound 2d which was almost 850-fold more active against HIV-1 than HIV-2 in human PBM cells (Table  1) . The selectivity of the new selenium containing pyrimidines 2b and 2d appears to be directed at HIV-1 and HIV-2, since none of these compounds were effective against herpes simplex virus type 1 in a plaque reduction assay in Vero cells when tested up to 100 fLM (data not shown). Compounds 2a and 2c also did not affect HSV-1 replication in Vero cells.
The degree of cross-resistance between the two most potent selenium compound 2b and 2d against a pair of AlT-resistant and sensitive virus obtained from the same patient was examined in human PBM cells (Larder et aI., 1990) .These compounds had about the same EC so value against the AlT-sensitive virus as found with the prototype HIV-1 strain LAV. A modest 3 to 12-fold increase in the EC so value was noted with the AlT-resistant virus compared to the pretherapy AlT-sensitive isolate ( Table  2 ). In contrast, the increased resistance to AlT between the AlT-sensitive and resistant virus was over 100-fold.
The effect of 6-phenylselenenyl analogues 2a-d on recombinant p51/66 HIV-1 RT in a cell free system was also determined (Table 1 and Fig. 1 ). Only compounds 2b and 2d exhibited anti-RT activity having an EC so of 69.8 fLM and 5.1 fLM, respectively. The anti-HIV-1 RT activity was unexpected since related 6-phenylselenenyl compounds had no effect on this enzyme (Goudgaon and Schinazi, 1991) . Nevertheless, the inhibition was 300-fold greater against virus replication than the viral enzyme, suggesting that inhibition of reverse transcriptase is not the primary mechanism of action ( Table 1) . None of the compounds evaluated inhibited DNA polymerase a purified from human PBM cells at concentration greater than 100 fLM.
In summary, based on limited structure-activity relationship, 1-(ethoxymethyl)-6-(phenylselenenyl)-5-ethyluracil 2d is the most promising candidate for AIDS chemotherapy among the 6-phenylselenenyl pyrimidines so far synthesized. Preclinical toxicological studies of this compound are currently in progress. Similar results were obtained when this experiment was repeated with different donor PBM cells.
Materials and Experimental procedures: chemistry
Melting points were determined on an Electrothermal IA 8100 digital melting point apparatus and are uncorrected. 1H NMR spectra were recorded on a General Electric QE-300 (300MHZ) spectrometer. Experiments were monitored using TLC analysis performed on Kodak chromatogram sheets precoated with silica gel and a fluorescent indicator, while column chromatography, employing silica gel (60-200 mesh; Fisher Scientific, Fair Lawn, NJ, USA)was used forthe purification of products. Tetrahydrofuran was freshly distilled from the sodium b:enzophenone salt. LOA (2.0M) and diphenyl diselenide were purchased from Aldrich Chemical Company (Milwaukee, WI, USA). Microanalyses were performed at Atlantic Microlabs (Atlanta, GA, USA).
General procedure for the preparation of 1-(ethoxymethyljpyrimidines 1a-d N,O-Bis(trimethylsilyl)acetamide (8.3ml, 34 mmol) was added dropwise under nitrogen to a stirred mixture of uracil analogue (14 mmol) and chloromethyl ethyl ether (1.3ml, 14 mmol) in dry CH 2CI2 (50ml). After 4 h of stirring at room temperature, the clear solution was cooled to O°Cand stannic chloride (1.7ml, 14 mmol) was added. The mixture was then warmed to room temperature and left to stir overnight. The reaction mixture was poured slowly into a mixture of cold saturated aqueous NaHC0 3 solution (100ml) and CHCI 3 (100ml). The resulting emulsion was separated by filtration through Cellte, the aqueous layer was extracted further with EtOAc (2 x 50ml) and the combined organic fraction dried over Na2S04' Concentration under reduced pressure, followed by trituration of the oily residue with ether afforded the corresponding product as colourless crystais. 1H NMR (COCI 3) 81.12 (t, J = 7.6Hz, 3H, 5-CH 2CH3), 1.21 (t, J = Antiviral selenium pyrimidines 265 6.8 Hz, 3H,o CH 3CH20), 2.37 (q, 2H, J = 7.6 Hz, 2H, 5-CH 2CH3), 3.59 (q, 2H, J = 6.8Hz, CH 3CH20), 5.13 (s, 2H, NCH 20), 7.07 (s, 1H, 6-H), 9.16 (s, 1H, NH, 0 20 exchangeable).
General procedure for the preparation of 1ethoxymethyl-6-(phenylselenenylj pyrimidines 2a-d LOA (2.0M, 2.5ml, 5 mmol) was added to a solution of acyclic pyrimidine (2 mmol) in dry THF (10ml) at -78°C dropwise with stirring under argon atmosphere. After the mixture was stirred for 1 h, diphenyl diselenide (1.25g, 4 mmol) dissolved in THF (10ml) was added and the temperature was maintained below -70°C. After 1 h below -70°C, the reaction mixture was quenched with AcOH (0.5ml), and the solution was allowed to warm to room temperature. The solution was concentrated to dryness in vacuo, and the residue was purified by silica gel column chromatography to give the corresponding 6-phenylselenenyl derivative. 1-(Ethoxymethyl}-6-(phenylselenenyl)uracil 2a. Purified by column chromatography using CHCb:MeOH (98:2). Yield 83%; m.p. 176--178°C (ethanol); 1H NMR (COC 3) 8 1.26 (t, J = 6.8 Hz, 3H, CH 3CH20), 3.65 (q, 2H, J = 6.8Hz, CH 3CH20), 5.28 (d, J = 11.2 Hz, 1H, 5.52 (s, 2H, NCH 20), 5H, SePh), 9.23 (s, 1H, NH, 0 20 exchangeable); Found C 48.01 %, H 4.37, N 8.58; C13H14N203Se requires C 48.01%, H 4.34, . Purified by column chromatography using CHCI 3:MeOH (98:2). Yield 85%; m.p. 134-135°C (ethanol); 1H NMR (COCI 3) 8 1.17 (t, J = 6.5 Hz, 3H, CH 3CH20), 1.98 (s, 3H, 5-Me), 3.57 (q, J = 6.5Hz, 2H, CH 3CH20), 5.63 (2, 2H, NCH 20), 5H, SePh), 9.35 (s, 1H, NH, 0 20 exchangeable); Found C 49.59%, H 4.77, N 8.26; C14H16N203Se requires C 49.57%; H 4.75, N 8.26, . Purified by column chromatography using CHCI 3:MeOH (96:4). Yield 76%; m.p. 128-130°C (ethanol); 1H NMR (COCI 3) 81.18 (t, J = 7.2 Hz, 3H, CH 3CH20), 3.58 (q, 2H, J = 7.2 Hz, CH 3CH20), 5.60 (s, 2H, NCH20), 7. 5H, SePh), 9.19 (s, 1H, NH, 0 20 exchangeable); Found C 45.57%; H 3.82, N 8.21: C13H13FN203Se requires C 45.50%, H 3.81, 
Materials and Experimental procedures: antiviral assays
The methods for determining the anti-HIV activity of the compounds in human PBM cells have been described previously (Schinazi et el., 1990: Goudgaon and Schinazi, 1991) . Stock solutions (5-10 mM)of the new compounds were prepared in pure OMSO and then diluted to the desired concentration. AZT was dissolved in water. HIV-1 (strain LAV) and HIV-2 (strain ROO-2), respectively, were obtained from Or Paul Feorino (Emory University) and Or Patricia Fultz (University of Alabama, Birmingham, AL, USA). AZT-resistant and sensitive viruses strain G910-6 and H112-2 were obtained from Or O. Richman {Veterans Affairs, San Diego CA, USA) through the NIH AIDS Research and Reference Programme and propagated in PBM cells as described previously (Schinazi et et., 1990) . The MOl used for infecting the cells was approximately 0.01 for all the antiviral assays.Virus obtained from the cell supernatant was quantitated on day 6 after infection by a reverse transcriptase assay using poly(rA)n.0Iigo(dT)12-18 as template-primer. At that MOl more than 250 kDPM mr' of RT activity was produced in untreated infected controls. The DMSO present in the diluted solution «0.1 %) had no effect on the virus yield. The toxicity of the compounds was assessed in human PBM (on day 6), Vero (on day 3) and CEM (on day 6) cells, as described previously (Schlnazi et a/., 1990) . The effect of the compounds on viral reverse transcriptase was determined using a recombinant p51/66 RT obtained from BioTechnology General Inc. (Rehovot, Israel).This enzyme had similar properties to virus particle derived from RT (data not shown). DNA polymerase ex, derived from human PBM cells, was used to determine the selectivity of the compounds for the cellular enzyme as described previously (Eriksson et al., 1989) . The protein concentration for the HIV-1 RT and DNA polymerase ex inhibition assays was approximately the same (0.02 JLg wetr'). The plaque reduction assays in Vero cells were performed with HSV-1 (strain F), as previously described (Schinazi et aI., 1982) . The EC so and IC so was obtained from the concentration-response curve using the median effective method described by Chou and Talalay (1984) .
